Neurocrine Biosciences Enters into Collaboration with Takeda for Osavampator Development
Tuesday, January 28, 2025
Neurocrine Biosciences has updated its partnership with Takeda to develop and commercialise osavampator (NBI-1065845/TAK-653), a potential first-in-class AMPA positive allosteric modulator aimed at treating major depressive disorder (MDD).
Osavampator is being developed as a treatment option for patients with MDD who have not responded adequately to at least one antidepressant during their current depressive episode. In April 2024, Neurocrine reported positive results from the Phase 2 SAVITRI™ study, which evaluated the drug in adult MDD patients.
MDD is a serious psychiatric condition characterised by persistent low mood, loss of interest, reduced energy, and difficulty concentrating, among other symptoms. It is a leading cause of disability globally and significantly increases the risk of suicide and overall mortality.
In the US, more than 21 million people are affected by MDD, with around one-third showing resistance to currently available antidepressants.
The amended agreement grants Neurocrine exclusive global rights to develop and commercialise osavampator for all indications, except in Japan, where Takeda will retain exclusive rights.
Under the revised terms, each company will independently fund development in their respective territories and will be entitled to royalty payments. Neurocrine plans to commence Phase 3 clinical trials for osavampator in the first half of this year, following a successful End-of-Phase 2 meeting with the US Food and Drug Administration (FDA).
The partnership between Neurocrine and Takeda, initiated in 2020, includes collaborative efforts to advance treatments for depression and schizophrenia.
The agreement originally covered osavampator, NBI-1070770, and a preclinical GPR139 antagonist development programme.
This updated collaboration aims to accelerate the development and availability of osavampator as a new treatment option for MDD patients worldwide.
Source: prnewswire.com
